AI assistant
Sending…
Oric Pharmaceuticals, Inc. — Director's Dealing 2021
Feb 3, 2021
32131_dirs_2021-02-02_c1074d14-f028-42d0-bef9-7173ab4cc222.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-02-01
Reporting Person: Chacko Jacob (Director, President and CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-01 | Stock Option (right to buy) | $29.83 | A | 280000 | Acquired | 2031-01-31 | Common Stock (280000) | Direct |
Footnotes
F1: 25% of the shares subject to the option shall vest on February 1, 2022, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
More from Oric Pharmaceuticals, Inc.
Proxy Solicitation & Information Statement
2026
Apr 28
Director's Dealing
2026
Feb 26
Regulatory Filings
2026
Feb 23
Annual Report
2026
Feb 23
Regulatory Filings
2026
Feb 23
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Jan 21
Director's Dealing
2026
Jan 21
Regulatory Filings
2026
Jan 16
Regulatory Filings
2026
Jan 16